Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norethindrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.73 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.73 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.73 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norethindrone SCHEMBL23390 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL14577661 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL19510084 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL5021649 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL14074493 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL7768886 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL24476231 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL11781372 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL9161897 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL11291575 | 0.97 | CYP3A4 (0.94) | CYP3A4LMNACYP2C19ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558316-A1 | USE OF CHYMASE INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS, POST-OPERATIVE FIBROSIS AND DISEASES WHICH ARE CHARACTERIZED BY FIBROSIS FORMATION | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-6753164-B2 | FOR DIAGNOSIS, PROPHYLAXIS AND THERAPY OF CANCER, INFLAMMATION, NEUROLOGICAL DISORDERS AND IMMUNE DISEASES AND/OR DISORDERS | HUMAN GENOME SCIENCES, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20020160491-A1 | Human Serpin polynucleotides, polypeptides, and antibodies | HUMAN GENOME SCIENCES, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6139873-A | CONTRACEPTIVES; HORMONE REPLACEMENT THERAPY | CEDARS-SINAI MEDICAL CENTER (US) | 2000-10-31 | — | — | US | disclosed |
| US-5962021-A | Combined pharmaceutical estrogen-androgen-progestin oral contraceptive | WAKE FOREST UNIVERSTIY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0929295-A4 | — | — | 1999-08-18 | — | — | EP | disclosed |
| EP-0929295-A1 | COMBINED PHARMACEUTICAL ESTROGEN-ANDROGEN-PROGESTIN ORAL CONTRACEPTIVE | WAKE FOREST UNIVERSITY (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998001115-A1 | COMBINED PHARMACEUTICAL ESTROGEN-ANDROGEN-PROGESTIN ORAL CONTRACEPTIVE | WAKE FOREST UNIVERSITY (US) | 1998-01-15 | — | — | WO | disclosed |